Gilead Sciences CEO Daniel Patrick O’Day sold 115,640 shares of common stock for $17.3 million after exercising options. The transaction was pre-arranged under a Rule 10b5-1 trading plan. This news comes amidst positive analyst sentiment for Gilead, driven by FDA approval for Yescarta in certain lymphoma cases and strong performance in its HIV pipeline, including the drug Yeztugo.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Gilead Sciences CEO O’Day sells $17.3 million in stock
Gilead Sciences CEO Daniel Patrick O’Day sold 115,640 shares of common stock for $17.3 million after exercising options. The transaction was pre-arranged under a Rule 10b5-1 trading plan. This news comes amidst positive analyst sentiment for Gilead, driven by FDA approval for Yescarta in certain lymphoma cases and strong performance in its HIV pipeline, including the drug Yeztugo.